Efficacy and Safety of Tildrakizumab in a Patient with Chronic HBV Infection

References

• Gudjonsson JE, Elder JT. Psoriasis: epidemiology. Clin Dermatol. 2007;25(6):535–546. doi:10.1016/j.clindermatol.2007.08.007
   PubMed Web of Science ®Google Scholar
• Megna M, Potestio L, Fabbrocini G, et al. Treating psoriasis in the elderly: biologics and small molecules. Expert Opin Biol Ther. 2022;22(12):1503–1520. doi:10.1080/14712598.2022.2089020
   PubMed Web of Science ®Google Scholar
• Megna M, Potestio L, Ruggiero A, et al. Guselkumab is efficacious and safe in psoriasis patients who failed anti-IL17: a 52-week real-life study. J Dermatolog Treat. 2022;33(5):2560–2564. doi:10.1080/09546634.2022.2036674
   PubMed Web of Science ®Google Scholar
• Valenti M, Narcisi A, Pavia G, Gargiulo L, Costanzo A. What Can IBD specialists learn from IL-23 trials in dermatology? J Crohns Colitis. 2022;16(Supplement_2):ii20–ii29. doi:10.1093/ecco-jcc/jjac023
   PubMed Web of Science ®Google Scholar
• Megna M, Potestio L, Camela E, et al. Ixekizumab and brodalumab indirect comparison in the treatment of moderate to severe psoriasis: results from an Italian single-center retrospective study in a real-life setting. Dermatol Ther. 2022;35(9):e15667. doi:10.1111/dth.15667
   PubMed Web of Science ®Google Scholar
• Ryu HH, Lee EY, Shin K, et al. Hepatitis B virus reactivation in rheumatoid arthritis and ankylosing spondylitis patients treated with anti-TNFalpha agents: a retrospective analysis of 49 cases. Clin Rheumatol. 2012;31:931–936. doi:10.1007/s10067-012-1960-1
   PubMed Web of Science ®Google Scholar
• Trépo C, Chan HL, Lok A. Hepatitis B virus infection. Lancet. 2014;384(9959):2053–2063. doi:10.1016/S0140-6736(14)60220-8
   PubMed Web of Science ®Google Scholar
• Nicoletta B, Alessandra N, Nevena S, et al. Management of psoriatic patients in biologic treatment associated with infectious comorbidities. Postepy Dermatol Alergol. 2020;37(3):417–421. doi:10.5114/ada.2020.96155
   PubMed Web of Science ®Google Scholar
• Perez-Alvarez R, Diaz-Lagares C, Garcia-Hernandez F, et al. Hepatitis B virus (HBV) reactivation in patients receiving tumor necrosis fac- tor (TNF)-targeted therapy: analysis of 257 cases. Medicine. 2011;90:359–371. doi:10.1097/MD.0b013e3182380a76
   PubMed Web of Science ®Google Scholar
• Duncan JR, Orlowski TJ, Elewski BE. Safety of guselkumab in hepatitis B virus infection. Dermatol Online J. 2019;25(10). doi:10.5070/D32510045827
   PubMedGoogle Scholar
• Qin H, Liu N, Hu Y, et al. Safety and efficacy of secukinumab in psoriasis patients infected with hepatitis B virus: a retrospective study. Eur J Dermatol. 2022;32(3):394–400.
   PubMed Web of Science ®Google Scholar
• Chiu HY, Hui RC, Huang YH, et al. Safety profile of secukinumab in treatment of patients with psoriasis and concurrent hepatitis B or C: a multicentric prospective cohort study. Acta Derm Venereol. 2018;98(9):829–834. doi:10.2340/00015555-2989
   PubMed Web of Science ®Google Scholar
• Megna M, Fabbrocini G, Gallo L, et al. A case of chronic HCV infection reactivation in a psoriasis patient treated with guselkumab. Curr Drug Saf. 2022;17(4):390–392. doi:10.2174/1574886317666220307112926
   PubMed Web of Science ®Google Scholar
• Koike Y, Fujiki Y, Higuchi M, et al. An interleukin-17 inhibitor successfully treated a complicated psoriasis and psoriatic arthritis patient with hepatitis B virus infection and end-stage kidney disease on hemodialysis. JAAD Case Rep. 2019;5(2):150–152. doi:10.1016/j.jdcr.2018.11.016
   PubMedGoogle Scholar
• Megna M, Patruno C, Bongiorno MR, et al. Hepatitis virus reactivation in patients with psoriasis treated with secukinumab in a real-world setting of Hepatitis B or Hepatitis C infection. Clin Drug Investig. 2022;42(6):525–531. doi:10.1007/s40261-022-01163-5
   PubMed Web of Science ®Google Scholar
• Peccerillo F, Odorici G, Pellacani G, et al. Secukinumab: a positive outcome in a patient with severe psoriasis and HBV-HCV co-infection. Dermatol Ther. 2018;31(4):e12601. doi:10.1111/dth.12601
   PubMed Web of Science ®Google Scholar
• Song EJ, Whitman P, Samsel J. The use of ustekinumab and guselkumab in a pediatric psoriasis patient with active hepatitis B infection. JAAD Case Rep. 2020;14(8):37–39.
   Google Scholar
• Gargiulo L, Pavia G, Valenti M, et al. Safety of biologic therapies in patients with moderate-to-severe plaque psoriasis and concomitant viral hepatitis: a monocentric retrospective study. Dermatol Ther. 2022;12(5):1263–1270. doi:10.1007/s13555-022-00726-w
   Web of Science ®Google Scholar
• Chen PY, Farrer S, Miranda-Cacdac L, et al. The use of interleukin 23 inhibitors in patients with chronic hepatitis B infection: a case series. JAAD Case Rep. 2022;30:1–4. doi:10.1016/j.jdcr.2022.09.023
   PubMedGoogle Scholar
• Gisondi P, Fargnoli MC, Amerio P, et al. Italian adaptation of EuroGuiDerm guideline on the systemic treatment of chronic plaque psoriasis. Ital J Dermatol Venerol. 2022;157(1):1–78. doi:10.23736/S2784-8671.21.07132-2
   PubMedGoogle Scholar
• Piaserico S, Messina F, Russo FP. Managing psoriasis in patients with HBV or HCV infection: practical considerations. Am J Clin Dermatol. 2019;20:829–845. doi:10.1007/s40257-019-00457-3
   PubMed Web of Science ®Google Scholar
• Strand V, Balsa A, Al-Saleh J, et al. Immunogenicity of biologics in chronic inflammatory diseases: a systematic review. BioDrugs. 2017;31:299–316. doi:10.1007/s40259-017-0231-8
   PubMed Web of Science ®Google Scholar
• Ruggiero A, Camela E, Potestio L, et al. Drug safety evaluation of tildrakizumab for psoriasis: a review of the current knowledge. Expert Opin Drug Saf. 2022;21(10):1249–1257.
   PubMed Web of Science ®Google Scholar
• Megna M, Potestio L, Fabbrocini G, et al. Tildrakizumab: a new therapeutic option for erythrodermic psoriasis? Dermatol Ther. 2021;34(5):e15030. doi:10.1111/dth.15030
   PubMed Web of Science ®Google Scholar
• Megna M, Tommasino N, Potestio L, et al. Real-world practice indirect comparison between guselkumab, risankizumab, and tildrakizumab: results from an Italian 28-week retrospective study. J Dermatolog Treat. 2022;33(6):2813–2820. doi:10.1080/09546634.2022.2081655
   PubMed Web of Science ®Google Scholar
• Ruggiero A, Potestio L, Cacciapuoti S, et al. Tildrakizumab for the treatment of moderate to severe psoriasis: results from a single center preliminary real-life study. Dermatol Ther. 2022;35(12):e15941. doi:10.1111/dth.15941
   PubMed Web of Science ®Google Scholar
• Megna M, Cinelli E, Gallo L, et al. Risankizumab in real life: preliminary results of efficacy and safety in psoriasis during a 16-week period. Arch Dermatol Res. 2022;314(6):619–623. doi:10.1007/s00403-021-02200-7
   PubMed Web of Science ®Google Scholar
• Yang K, Oak ASW, Elewski BE. Use of IL-23 inhibitors for the treatment of plaque psoriasis and psoriatic arthritis: a comprehensive review. Am J Clin Dermatol. 2021;22(2):173–192. doi:10.1007/s40257-020-00578-0
   PubMed Web of Science ®Google Scholar
• Megna M, Potestio L, Ruggiero A, et al. Risankizumab treatment in psoriasis patients who failed anti-IL17: a 52-week real-life study. Dermatol Ther. 2022;35(7):e15524. doi:10.1111/dth.15524
   PubMed Web of Science ®Google Scholar
• Camela E, Potestio L, Ruggiero A, et al. Towards personalized medicine in psoriasis: current progress. Psoriasis. 2022;1(12):231–250. doi:10.2147/PTT.S328460
   Google Scholar